Volume | 905,612 |
|
|||||
News | - | ||||||
Day High | 1.81 | Low High |
|||||
Day Low | 1.76 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cronos Group Inc | CRON | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.81 | 1.76 | 1.81 | 1.77 | 1.80 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,479 | 905,612 | $ 1.78 | $ 1,608,535 | - | 1.665 - 3.616 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:56:51 | 1 | $ 1.79 | USD |
Cronos Group Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 670.24M | 380.82M | 376.10M | $ 20.14M | $ -193.38k | -0.05 | -3,465.86 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 1.08M | 2.80% |
Cronos News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRON Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.82 | 2.03 | 1.76 | 1.90 | 1,148,965 | -0.06 | -3.3% |
1 Month | 1.84 | 2.03 | 1.665 | 1.86 | 1,084,479 | -0.08 | -4.35% |
3 Months | 2.12 | 2.14 | 1.665 | 1.92 | 1,360,857 | -0.36 | -16.98% |
6 Months | 3.15 | 3.616 | 1.665 | 2.30 | 1,573,088 | -1.39 | -44.13% |
1 Year | 3.05 | 3.616 | 1.665 | 2.71 | 1,767,464 | -1.29 | -42.3% |
3 Years | 6.89 | 15.83 | 1.665 | 6.40 | 3,002,058 | -5.13 | -74.46% |
5 Years | 6.00 | 25.0999 | 1.665 | 10.18 | 5,525,436 | -4.24 | -70.67% |
Cronos Description
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann. |